These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26382807)

  • 21. Early Surgical Intervention is Beneficial in Avoiding Complications in Patients with Male Lower Urinary Tract Symptoms.
    Bachmann A; Rapoport LM; Wetterauer C
    Eur Urol Focus; 2018 Jan; 4(1):2-3. PubMed ID: 29680700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
    Kruep EJ; Phillips E; Hogue S; Eaddy M
    Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms.
    Kosilov K; Kuzina I; Kuznetsov V; Kosilova L; Ivanovskaya M; Kosilova E
    Curr Aging Sci; 2020; 13(1):72-80. PubMed ID: 31560296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
    Fusco F; Arcaniolo D; Creta M; Piccinocchi G; Arpino G; Laringe M; Piccinocchi R; Longo N; Verze P; Mangiapia F; Imperatore V; Mirone V
    World J Urol; 2015 May; 33(5):685-9. PubMed ID: 25491675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
    Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
    Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in asian men.
    Kaplan SA
    J Urol; 2014 May; 191(5):1345. PubMed ID: 24745512
    [No Abstract]   [Full Text] [Related]  

  • 28. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re: Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2013 Sep; 190(3):979. PubMed ID: 23931215
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 31. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
    Vinarov AZ; Spivak LG; Mironov AV
    Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
    Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
    Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: Matthias Oelke, François Giuliano, Vincenzo Mirone, et al., monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25.
    Gacci M; Maggi M; Carini M
    Eur Urol; 2012 Sep; 62(3):e63-4. PubMed ID: 22709717
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia.
    Ng CF; Yee CH; So WY; Yip SK; Wu E; Yau P
    Hong Kong Med J; 2017 Jun; 23 Suppl 2(3):35-37. PubMed ID: 29938670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.